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Abstract
Chemotherapy is commonly used as a major therapeutic option for breast cancer treatment, but its efficacy is often diminished by
disruption of patient's anti-tumor immunity. Chemotherapy-generated tumor cell debris could hijack accumulated tumor-associated
macrophages (TAMs), provoking tumor recurrence. Therefore, reprogramming TAMs to acquire an immunocompetent phenotype
is a promising strategy to potentiate therapeutic efficacy. In this study, we analyzed the proportion of immune cells in the breast
cancer patients who received chemotherapy. To validate our findings in vivo, we used a syngeneic murine breast cancer (4T1) model.
Chemotherapy generates an immunosuppressive tumor microenvironment in breast cancer. Here, we show that phagocytic engulf-
ment of tumor cell debris by TAMs reduces chemotherapeutic efficacy in a 4T1 breast cancer model. Specifically, the engulfment of
tumor cell debris by macrophages reduced M1-like polarization through heme oxygenase-1 (HO-1) upregulation. Conversely,
genetic or pharmacologic inhibition of HO-1 in TAMs restored the M1-like polarization. Our results demonstrate that tumor cell
debris-induced HO-1 expression in macrophages regulates their polarization. Inhibition of HO-1 overexpression in TAMs may pro-
voke a robust anti-tumor immune response, thereby potentiating the efficacy of chemotherapy.
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Introduction
Breast cancer, one of the most commonly diagnosed malignancies in
women worldwide, is often treated with chemotherapy [1]. After
chemotherapy, however, unwanted host effects provoke tumor recurrence
and increase cancer cell aggressiveness, often via disruption of the patient's
immune system [2,3]. The response to chemotherapy is affected by the
tumor microenvironment (TME), which is the complex niche where can-
cer cells interact with the tumor stroma [4,5]. Chemotherapy can alter the
proportion and activity of immune cells, including CD8+ cytotoxic T lym-
phocytes that play major roles in reducing cancer progression [6–8].
Accordingly, potentiating the functional activity of cytotoxic lymphocytes,
including CD8+ T cells, has become a central goal of many anti-tumor
therapies. One example of this is the combined use of chemotherapeutic
agents plus immune-stimulators that target anti-tumor immunity [5].
The number of tumor-associated macrophages (TAMs) infiltrated into
tumors is increased following chemotherapy [9]. TAMs, which act as a
bridge between innate and adaptive immunity, could potentially be tar-
geted to complement chemotherapeutic efficacy [10]. Notably, TAMs
have dual roles in cancer development and progression [10]: those associ-
ated with poor clinical outcome display the M2-like macrophage (alterna-
tively activated) phenotype which promotes tumor progression through
immunosuppression [10], whereas those induced by local signals display
the M1-like macrophage (classically activated) phenotype associated with
cytotoxic and T-cell-mediated anti-tumor activities [10,11]. Recent stud-
ies have focused on the modulation of signaling factors and events to skew
TAMs toward M1-like TAMs for enhancing the host anti-tumor response
[12–14].
For decades, anti-cancer therapies have been primarily intended to
destroy cancer cells to reduce tumor growth [15,16]. When such therapies
kill tumor cells, tumor cell debris (apoptotic cells, necrotic cells and cell
fragments) can be generated and released to the surrounding area [15].
Importantly, the tumor cell debris generated by chemotherapy can con-
tribute to accelerating tumor growth [15,17]. Macrophages critically
remove dead cells [18,19], and their phagocytosis of apoptotic cancer cells
has been suggested to promote tumor growth by modulating TAM activity
[20–22]. However, the molecular mechanisms underlying the interaction
between tumor cell debris and TAMs remain largely unresolved.
Chemotherapy-induced oxidative stress is one mechanism by which
cancer cells are killed [23]. However, cancer cells can bypass oxidative cell
death by activating their anti-oxidant defense system [23–25]. The over-
expression of stress-responsive antioxidative enzyme, heme oxygenase-1
(HO-1) was reported to be associated with poor prognosis in breast cancer
patients receiving chemotherapy [24,26]. Conversely, HO-1 inactivation
can promote the effectiveness of anti-cancer therapy to inhibit tumor
growth [26–29]. Recent studies suggest that the induction of HO-1 in
TAMs plays an important role in cancer progression [26,30,31]. However,
the role of overexpressed HO-1 in TAMs during chemotherapy remains
poorly understood. Here we report that breast tumor cell debris-induced
HO-1 expression in TAMs can diminish the efficacy of paclitaxel




This study was approved by the institutional review board (IRB) of
Seoul National University Hospital (Seoul, South Korea), and all patients
provided signed informed consent for collection of specimens (IRB num-
ber: 1807-061-957). The tumor specimens were kindly supplied by Prof.
Wonshik Han of Seoul National University Hospital.
Animal study
Balb/c mice (6  9 weeks old) were purchased from Orient Bio
(Gyeonggi-Do, South Korea). HO-1 KO mice, in which the HO-1 gene
was deleted by targeted gene knockout, were kindly provided by Dr. M.A.
Perrella (Harvard Medical School, Boston, MA, USA). 4T1 murine mam-
mary adenocarcinoma cells (1  105) were subcutaneously implanted in
the mammary glands of female Balb/c mice as previously described [32].
Tumors were grown for 10 days before mice were injected with PTX.
The tumor size was measured by caliper
(width  length  height  0.52 = mm3). All the animals were main-
tained according to the relevant institutional animal care guidelines. Ani-
mal experimental procedures were approved by the institutional animal
care and use committee at Seoul National University, South Korea
(IACUC number: SNU-170710-2)
Cell culture
To generate primary bone marrow-derived macrophages (BMDMs),
we obtained bone marrow cells by flushing the long bones of mice
(6  12 weeks old). Bone marrow cells were plated in DMEM supple-
mented with 10% fetal bovine serum (FBS; Gibco, #16000-044),
100 lg/ml streptomycin, 100 U/ml penicillin and 20 ng/ml M-CSF
(Biolegend, #576406) and cultured for 7 days to allow for macrophage dif-
ferentiation. Murine 4T1 cells were purchased from the American Type
Culture Collection (ATCC) and cultured in DMEM supplemented with
10% FBS, 100 lg/ml streptomycin and 100 U/ml penicillin. Cells were
maintained at 37 C in a humidified atmosphere of 5% CO2.
Macrophage polarization
To generate M1-like polarized macrophages, BMDMs were incubated
with 100 ng/ml of lipopolysaccharide (LPS; Sigma, #L2630) for 24 h as
previously described [14].
Generation of tumor cell debris
Tumor cell debris was generated by incubating breast cancer cells
(1  107) in medium supplemented with PTX (1 mM) for 24 h. The
presence of dead cells among the debris was confirmed by the annexin
V/propidium iodide (PI) assay.
Isolation of single cells from mouse tumors
Tumors were collected from mice and dissociated into single cells as
described previously [33]. Specifically, tumor implanted mice were euth-
anized and tumors were harvested. Tumors were then minced and
mechanically disaggregated. The disaggregated tumors were then passed
through a 40 mm filter using DMEM supplemented with 2% FBS to pre-
pare a single cell suspension.
Flow cytometric analysis
Single-cell suspensions were washed with phosphate-buffered saline
(PBS) containing 1% FBS and non-specific antibody binding was blocked
with anti-mouse CD16/32 Fc receptor block antibody (Biolegend
#101319). The cells were then stained by incubation on ice for 30 min
with the following fluorescence-conjugated antibodies: anti-mouse
CD45 APC (clone I3/2.3, Biolegend #147708), anti-mouse F4/80
PerCP/Cy5.5 (clone BM8, Biolegend #123128), anti-mouse F4/80
APC (clone BM8, Biolegend #123116), anti-mouse CD3e Alexa Fluor
700 (clone 500A2, Biolegend #152316), anti-mouse CD8a PE/Cy7
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(clone 53-6.7, Biolegend #100722), anti-mouse CD206 FITC (clone
C068C2, Biolegend #141704). The cells were washed with PBS and sub-
jected to flow cytometry. Dead cells were excluded by 40,6-diamidino-2-
phenylindole (DAPI; Thermo Fisher Scientific, #D1306) staining.
For intracellular staining, cells were fixed and permeabilized with a fix-
ation/permeabilization buffer set (Thermo Fisher Scientific, #00-5521-
00), and then stained with the following antibodies: anti-mouse IL-
12p40 PE (clone C15.6, Biolegend #505204), anti-mouse TNF-a FITC
(clone MP6-XT22, Biolegend #506304).
To examine the presence of EpCAM as an intracellular marker of
breast tumor cell debris, cells were fixed with 2% formaldehyde in PBS
for 30 min at room temperature, permeabilized with 0.1% Tween-20 in
PBS for 15 min at room temperature, and stained with anti-mouse
EpCAM FITC (clone G8.8, Biolegend #118208). We used FACS Cal-
ibur, LSR Fortessa X-20 and FACS Aria III (BD) machines for the
above-listed analyses. All samples were analyzed using the Flow jo software
package (Tree Star).
Cell sorting
Single-cell suspensions obtained from tumors were stained with DAPI,
anti-CD45 APC (clone I3/2.3, Biolegend #147708) and anti-CD11b
Alexa Fluor700 (clone M1/70, Biolegend #101222) and subjected to
FACS using a FACS Aria III (BD). Live cells were identified as DAPI neg-
ative and TAMs as CD45+ CD11b+F4/80+ populations.
Immunofluorescence
Tumor specimens were fixed, paraffin-embedded and sectioned. The
sections were deparaffinized and rehydrated by serial washes with graded
xylene and alcohol. For immunofluorescence staining, tissue sections were
boiled in 10 mM sodium citrate (pH 6), subjected to serial washing,
blocked with 5% FBS in PBST (PBS + 0.1% Tween 20) and co-stained
with HO-1 (Enzo, #ADI-OSA-111-D), CD8 Alexa Fluor 594 (clone
RPA-T8, Biolegend #301056), CD11b Alexa Fluor 488 (clone M1/70,
Biolegend #101217), CD206 (clone 15-2, Biolegend #321101), epider-
mal growth factor receptor (EGFR; Santa Cuz #sc-03G) or epithelial cell
adhesion molecule EpCAM (Santa Cuz #sc-25308) and DAPI (Thermo
Fisher Scientific) overnight at 4 C. To analyze the phagocytosis of macro-
phages, the isolated myeloid cells were incubated with F4/80 (Santa Cruz).
The resulting CD11b+ F4/80+ cells were dispensed to glass slides, perme-
abilized for 5 min at room temperature using 0.2% Triton X-100 in PBS
and blocked with 3% bovine serum albumin (BSA) in PBS containing
0.1% Triton X-100 for 1 h at room temperature. Anti-mouse EpCAM
Alexa Fluor 594 (clone G8.8, Biolegend #118222) was used to stain
tumor cell debris engulfed in macrophages. To assess the expression of
HO-1 in macrophages, myeloid cells were incubated with F4/80 (Santa
Cruz), permeabilized, stained with HO-1 (Enzo #ADI-OSA-111-D)
and incubated with the appropriate secondary antibodies. Nuclei were
counterstained with DAPI and immunofluorescence images were collected
on a Zeiss LSM 710 confocal microscope (Zeiss).
Quantitative PCR (qPCR)
Total RNA was isolated from cells and tumor tissues using the
TRIzolTM reagent (Invitrogen) according to the manufacturer's instruc-
tions and reverse transcribed using Moloney murine leukemia virus reverse
transcriptase (Promega). qPCR analysis was performed using a 7300 Real-
Time PCR System (Thermo Fisher Scientific). Gene expression data are
presented after normalization with an internal control. The following pri-
mers were utilized:










Whole-cell lysates or tumor extracts were prepared by suspending the
cells or tumor tissues in lysis buffer (Cell Signaling Technology) contain-
ing protease inhibitors (Roche) on ice, followed by centrifugation for
15 min at 13,000g. Protein concentrations were assessed by a BSA assay
(Invitrogen). Proteins were resolved by sodium dodecyl sulfate polyacry-
lamide gel electrophoresis (SDS–PAGE) and transferred to PVDF mem-
branes (Gelman Laboratory). The membranes were incubated with
primary antibodies at 4 C overnight, washed and incubated with horse-
radish peroxidase-conjugated secondary antibodies. The results were devel-
oped with ECL reagents (Amersham Pharmacia Biotech) according to the
manufacturer's instructions and visualized using a LAS 4000 (Fujifilm Life
Science).
Statistics
Data are presented as the mean þ SEM (standard error of the mean).
For between-group differences in the mouse experiments, significance
was determined using one-way ANOVA analysis with a Tukey's post
hoc test. The Student's t-test was used to compare data from control
and experimental conditions. The analyses were applied using SigmaPlot
12 (Systat Software).
Results
Chemotherapy facilitates the development of an immunosuppressive
TME in breast cancer
Chemotherapy acts as a double-edged sword in the regulation of cancer
progression [16,34]. Therapy-induced changes of the TME often abrogate
treatment efficacy via unwanted host effects, such as modification of
immune cell infiltration and increased production/secretion of immuno-
suppressive factors [4]. To assess the chemotherapy-associated changes
in immune cell subsets, we measured the proportion of immune cells in
the breast cancer patient who received chemotherapy. Immunofluores-
cence staining revealed that the number of intratumoral CD8+ T lympho-
cytes (Fig. 1a) was reduced, while that of M2-like TAMs (identified by
positivity for CD206) was increased in tumor tissues after chemotherapy
(Fig. 1b).
Next, we examined the impact of cytotoxic therapy on anti-tumor
immunity in the TME. For this purpose, we used a syngeneic murine
breast cancer (4T1) model in which mice were treated with PTX, one
of the most commonly used chemotherapeutic agents [29,35,36]. To
determine whether PTX treatment altered the proportion of tumor-
infiltrating immune cells, we analyzed infiltrating immune cells stained
with fluorochrome-conjugated antibodies by flow cytometry [37]. We
examined the proportion of CD8+ cytotoxic T lymphocytes, which play
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a decisive role in suppressing tumor growth, and found that the percentage
of recruited CD8+ T cells was significantly reduced in the PTX-treated
group (Fig. 2a).
Phagocytosis of tumor cell debris regulates the polarization of
macrophages to a pro-tumor phenotype
Chemotherapy affects the polarization of TAMs in a way conferring
immunosuppressive functions that suppress anti-tumor immunity
[31,38,39]. To understand how PTX therapy alters the TAM phenotype,
we considered the physiological events that characterize the TME after
cytotoxic therapy. Given that macrophages function to clear tumor cell
debris in the TME [18], we examined whether phagocytosis of the tumor
cell debris generated by chemotherapy could contribute to TAM polariza-
tion. The proportion of macrophages phagocytosing breast tumor cell deb-
ris (identified by positivity for the breast cancer cell marker, EpCAM+) was
increased after PTX treatment (Fig. 2b). We observed that tumor cell deb-
ris (EpCAM+) was engulfed by macrophages (F4/80+ cells) from 4T1
tumor-bearing mice injected with PTX (Fig. 2c).
To investigate the role of tumor cell debris in the polarization of
macrophages, we co-cultured BMDMs with 4T1 breast cancer cells trea-
ted with PTX for 24 h. PTX-induced cell death was confirmed by annexin
V/PI staining. Notably, the mRNA levels of Tnf and Il12b were reduced
in M1-like polarized BMDMs co-cultured with cancer cell debris (Fig. 2d,
e). To investigate whether tumor cell debris could affect the polarization of
macrophages to the M2-like phenotype, we examined the expression of
the M2-like macrophage marker, CD206 in macrophages co-cultured
with tumor cell debris or live breast cancer cells. The CD206 expression
Fig. 1. Chemotherapy alters the proportion of tumor-infiltrating immune cells. (a) Representative images of tumor sections from the patients with
breast cancer before and after chemotherapy, stained for the presence of CD8+ cytotoxic T cells. The EGFR expression was measured as a cancer cell
marker. (b) Representative images of tumor tissues from breast cancer patients receiving chemotherapy, stained for CD206, a marker for M2-like TAMs.
**P < 0.01.
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Fig. 2. Tumor cell debris formed during chemotherapy contributes to macrophage polarization. (a) Mice were implanted subcutaneously in the
mammary gland with 4T1 tumor cells. At 10 days after tumor cell injection, the mice were subjected to intraperitoneal injection of vehicle or PTX (5 mg/
kg) every 5 day. Mice were sacrificed on day 15 after PTX treatment, and tumors were collected. Effects of PTX on the proportion of CD45+CD3+CD8+
tumor-infiltrating lymphocytes were analyzed. Whole tumors were dissociated into single cells and flow cytometry was used to identify tumor-infiltrating
immune cells. The proportion of CD45+CD3+CD8+ tumor-infiltrating lymphocytes in tumors collected from mice treated with or without PTX was
assessed by flow cytometry. (b) Phagocytosis of breast tumor cell debris was analyzed as the proportion of macrophages found to contain intracellular
EpCAM, as assessed by flow cytometry. (c) Whole tumors were processed into single cells. CD45+CD11b+ myeloid cells were isolated, cytospun onto
glass slides, and subjected to immunofluorescence analysis for identification of breast tumor cell debris (EpCAM+) phagocytosed by macrophages (F4/
80+). (d, e) BMDMs were treated with 100 ng/ml LPS for 24 h to cause them to skew toward the M1-like phenotype. The mRNA expression levels of
Tnf (d) and Il12b (e) in the M1-like polarized macrophages treated with or without 4T1 cell debris for 30 h were measured by qPCR. (f) Macrophages
were co-cultured with live 4T1 cells or 4T1 tumor cell debris for 24 h, and the CD206 expression of macrophages was analyzed by flow cytometry. The
significance of differences between groups was determined by one-way ANOVA (Tukey's post hoc test) and the Student's t-test was used to compare
results obtained from the control and experimental conditions. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Fig. 3. Phagocytosis of tumor cell debris induces HO-1 expression in macrophages. (a) Representative images of CD11b and HO-1 expressed in
tumor tissues from breast cancer patients before and after chemotherapy. (b) Representative immunofluorescence images of HO-1 expression in TAMs
from 4T1 breast cancer-bearing mice. (c) The protein expression levels of HO-1 in macrophages co-incubated for 8 h with tumor cell debris generated
from murine 4T1 measured by Western blot analysis. (d) The HO-1 expression levels of macrophages (F4/80+) cultured with live cancer cells or tumor
cell debris analyzed by flow cytometry. Comparisons between the control and experimental groups were performed with the Student's t-test. One-way
ANOVA (Tukey's post hoc test) was used to determine the significance of differences between groups. *P < 0.05 and **P < 0.01.
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levels of macrophages were higher in macrophages treated with tumor cell
debris compared to those co-cultured with live breast cancer cells (Fig. 2f).
Likewise, BMDMs co-incubated with breast tumor cell debris showed ele-
vated mRNA levels of Il10 which is an immunosuppressive M2-like mar-
ker (Supplemental Fig. S1a). These results suggest that engulfment of
tumor cell debris causes an immunosuppression, which can be an impor-
tant aspect of the TME changes seen in the wake of anti-cancer therapy.
Engulfment of tumor cell debris induces HO-1 expression in
macrophages
Chemotherapy used for tumor eradication in breast cancer patients has
been reported to upregulate HO-1 expression, which is associated with the
low survival rate [23,26]). Moreover, TAMs represent the major tumoral
source of HO-1 in breast cancer [26]. To determine whether HO-1
Fig. 4. HO-1 expression induced by is involved in the modulation of macrophage polarization. (a, b) BMDMs from WT or HO-1 KO mice were
treated with LPS (100 ng/ml) for 24 h. The resulting M1-like polarized macrophages were co-cultured with 4T1 tumor cell debris for 30 h. The
proportion of macrophages expressing TNF-a (a) and IL-12p40 (b) was determined by flow cytometry. (c) BMDMs from WT or HO-1 KO mice were
co-treated with 4T1 tumor cell debris for 24 h, and the expression of CD206 in macrophages was analyzed by flow cytometry. (d) BMDMs from WT or
HO-1 KO mice were co-cultured with or without 4T1 tumor cell debris for 8 h, and the mRNA levels of Il10 were analyzed by qPCR. *P < 0.05 and
***P < 0.001. NS: not significant.
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Fig. 5. Inactivation ofHO-1 sensitizes the host response to PTX therapy. (a)WT orHO-1 KOmice implanted with 4T1 tumors were intraperitoneally
injected with vehicle or PTX (5 mg/kg) for 5 days.Mice were killed on day 15 after PTX treatment, and tumors were collected. Tumor volume as a% change
was calculated and plotted as the total mean þ SEM. (b) Mice implanted with 4T1 tumor cells received vehicle or PTX (5 mg/kg) for 5 days with or without
daily intraperitoneal injection of ZnPP (40 mg/kg). Mice were sacrificed on day 15 after PTX treatment, and tumors were collected. Tumor volume was
calculated as a relative change and plotted as the totalmean þ SEM. (c) Representative images of tumor sections stained for CD8+T cells andDAPI are shown.
The significance of the differences between experimental groups was determined using one-way ANOVA (Tukey's post hoc test). *P < 0.05 and ***P < 0.001.
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expression of TAMs was enhanced after chemotherapy, the HO-1 expres-
sion in macrophages in breast cancer patient samples collected before and
after chemotherapy was measured. In macrophages of breast cancer
patients following chemotherapy, overexpression of HO-1 was confirmed
(Fig. 3a). The elevated expression of HO-1 in TAMs derived from 4T1
tumor-bearing mice injected with PTX was confirmed by immunofluores-
cence staining (Fig. 3b).
In another experiment, BMDMs co-cultured with tumor cell debris
induced HO-1 expression to a greater extent than did the untreated group
(Fig. 3c). To further determine whether tumor cell debris is critical for the
overexpression of HO-1 in macrophages following chemotherapy, the
expression levels of HO-1 in macrophages co-cultured with live breast can-
cer cells or PTX-generated tumor cell debris were compared. Macrophages
co-incubated with breast cancer cell debris showed significantly higher
levels of HO-1 than those co-cultured with live breast cancer cells
(Fig. 3d).
HO-1 overexpression triggered by phagocytosis of tumor cell debris
regulates the polarization of macrophage
Considering that HO-1 is an important factor for the polarization of
macrophages, it could be a promising target in cancer immunotherapy
[10,40]. To test whether the tumor cell debris-induced HO-1 overexpres-
sion in macrophages is essential for their polarization, we used HO-1-
deficient BMDMs from HO-1 knockout (HO-1 KO) mice. First, we
examined whether ablation of HO-1 could affect the activation of M1-
like polarized macrophages treated with tumor cell debris. The proportion
of M1-like macrophages, as assessed by the upregulated expression of
TNF-a and IL-12p40, was significantly decreased in wild-type (WT) cells
co-cultured with 4T1 tumor cell debris, whereas HO-1 KO macrophages
were unaffected by this treatment (Fig. 4a, b). To further explore the role
of HO-1 activity in macrophage polarization, we used zinc protoporphyrin
IX (ZnPP), which is a pharmacologic inhibitor of HO-1. We found that
the ZnPP-mediated inhibition of HO-1 activity restored the mRNA levels
of Tnf and Il12b in M1-like polarized macrophages co-cultured with 4T1
tumor cell debris (Supplemental Fig. S1b, c).
Next, we examined whether inhibition of HO-1 activity could affect
M2-like polarization. The expression of CD206 in HO-1-deficient macro-
phages treated with tumor cell debris was lower than that in WT macro-
phages (Fig. 4c). HO-1-deficient macrophages treated with tumor cell
debris showed decreased mRNA levels of Il10 compared to the WT
macrophages (Fig. 4d). Taken together, these results suggest that HO-1
signaling induced by tumor cell debris represses the M1-like polarization
of macrophages in the TME following chemotherapy.
HO-1 inactivation amplifies the therapeutic efficacy of PTX
To determine whether HO-1 inactivation could enhance the therapeu-
tic efficiency of PTX, we used HO-1 KO mice implanted with 4T1 breast
cancer cells. We injected PTX into the mice when tumors were grown for
10 days. Notably, the therapeutic efficacy of PTX was increased in HO-1
KO mice compared to the WT mice (Fig. 5a). However, the tumor weight
was not that much different between HO-1 WT and KO mice treated
with PTX due to the relatively larger size of initial tumors at the time point
of PTX injection (Supplemental Fig. S2a and Fig. S2b).
To further confirm the role of HO-1 in the response to PTX, 4T1
tumor cell-implanted mice were injected with PTX and the HO-1 inhibi-
tor, ZnPP. We found that co-treatment of mice with ZnPP and PTX sup-
pressed tumor growth more effectively than PTX treatment alone
(Fig. 5b). The pharmacologic inhibition of HO-1 resulted in a further
decrease of the tumor weight compared to PTX treatment alone (Supple-
mental Fig. S2c). In the context of an anti-tumor immune response, suf-
ficient numbers of infiltrating T cells are needed to achieve a favorable
clinical outcome [13,41]. In Balb/c mice implanted with 4T1 tumor cells,
PTX administration significantly reduced the proportion of CD8+ cyto-
toxic T lymphocytes, but this was restored by HO-1 inhibition with ZnPP
(Fig. 5c).
Discussion
For decades, various anti-tumor therapies have utilized a wide array of
strategies in an attempt to eliminate tumors [15]. However such therapies
can trigger massive changes in aspects of the immune contexture, includ-
ing the density, location and composition of tumor-infiltrating immune
cells [13,42]. Cytotoxic therapy can shift the TME toward an immuno-
suppressive microenvironment, so strategies to maintain a durable anti-
tumor immune response during chemotherapy are desirable [5,13,35].
In this context, reprogramming the TME to an immunogenic phenotype
may potentiate therapeutic efficacy for tumor regression [43].
Tumor cell debris produced during chemotherapy has been shown to
stimulate tumor growth, and this is a critical problem for cancer therapy
[15,17]. Phosphatidylserine presented on the surface of tumor cell debris
can provoke an immunosuppressive condition in TME [19]. A
chemotherapy-induced generation of an immunosuppressive TME influ-
ences macrophage polarization, which may account for the poor therapeu-
tic response [20,44]. These findings suggest that tumor cell debris
generated during chemotherapy undergoes phagocytosis by macrophages,
and this inhibits manifestation of the M1-like macrophage phenotype,
thereby dampening the anti-tumor immune response. Therefore,
chemotherapeutic strategies that focus on killing cancer cells may act as
a double-edged sword.
HO-1 plays an important role in the maintenance of homeostasis.
However, it has been reported that HO-1 may also promote tumor pro-
gression [25]. We found that the tumors initially grown in HO-1 KO
mice implanted with 4T1 murine mammary adenocarcinoma cells were
larger than those formed in the WT mice while they were shrunken to
a greater extent after PTX treatment. We speculate that HO-1 may have
a tumor suppressive function in the early stage of carcinogenesis. Upon
chemotherapy, however, HO-1 may stimulate the tumor growth. In the
TME, TAMs are a major source of HO-1, which mediates immune sup-
pression in breast cancer [26,45]. Here, we demonstrate that engulfed
breast tumor cell debris stimulates the HO-1 expression in macrophages
and thereby inhibits M1-like macrophage polarization. Conversely, inacti-
vation of HO-1 in macrophages enhances therapeutic efficacy by polariz-
ing them toward the M1-like phenotype.
Impairment of LC3-associated phagocytosis followed by engulfment of
dying cancer cells was previously shown to regulate the polarization of
macrophages toward the M1-like phenotype [22]. This raises the possibil-
ity that tumor cell debris-induced HO-1 overexpression may regulate the
immunomodulatory signaling of macrophage polarization via the LC3-
associated phagocytosis pathway. Collectively, these results suggest that
targeting HO-1 overexpressed in macrophages engulfing tumor cell debris
could be a potential strategy to promote chemotherapeutic efficacy by
switching macrophages to an immune-stimulatory phenotype.
Potentiation of the immunogenic function of M1-like TAMs is critical
for proper T cell activation in the TME [12,46,47]. Typically, M1-like
TAMs mediate the influx of T cells through production of T cell chemoki-
nes [12,39]. Abundant accumulation of M1-like TAMs and CD8+ T cells
in a tumor has been associated with favorable patient outcomes and thus
may be a critical component of anti-tumor therapy [42]. Here, the
increased proportion of CD8+ T cells was shown in a 4T1 tumor model
upon treatment with PTX and a HO-1 inhibitor. Together, these findings
suggest that the polarization of TAMs toward the M1-like phenotype
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through HO-1 inhibition converts an immunosuppressive TME to an
immunogenic one during chemotherapy.
Immune checkpoint blockade therapy (e.g., with anti-CTLA-4 and
PD-1), which is a firmly established treatment for cancer, acts against a
variety of tumor types by enhancing anti-tumor immunity [41,48]. How-
ever, only a small proportion of patients show a clinical response to this
therapy, suggesting that other immune-modulatory treatments might be
required for better therapeutic outcome [26,41,49]. The failure of
immune checkpoint inhibitors is likely to reflect the immunosuppressive
nature of the TME [7]. Reprogramming TAMs toward an immune-
stimulatory phenotype enhances the activity of immune checkpoint inhi-
bitors [12,14,49]. Thus, it will be worthwhile to determine whether the
M1-like TAMs induced by HO-1 inactivation could improve the response
to immune checkpoint inhibitors.
In summary, TAM-mediated phagocytosis of breast tumor cell debris
diminishes therapeutic efficacy by decreasing the proportion of M1-like
TAMs after chemotherapy. Specifically, we reveal that tumor cell debris-
induced HO-1 expression in macrophages affects their polarization in
the direction of immunosuppression upon chemotherapy (Fig. 6), and
that inhibition of HO-1 overexpression in TAMs can create a robust
anti-tumor immune response to potentiate the efficacy of chemotherapy.
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